Do young, early-stage breast cancer patients with pCR to chemoimmunotherapy still benefit from PMRT?

Topics: Breast Cancer • Radiation Oncology

If a patient in her 30s with a cT2N0 triple negative breast cancer has a pathologic complete response (pCR) after chemo/immunotherapy at the time of mastectomy, do you still feel they would benefit from PMRT?

Answer from: Radiation Oncologist at Community Practice

As far as I am aware, it is not part of the usual practice to offer PMRT in the setting of T2N0 TN breast cancer. Though I think it may be considered as an "out of the box" recommendation in the setting of multiple high-risk features (larger T2 size, poor response to neo-adjuvant tx, LVI, young age,...

Comments

Radiation Oncologist at Lake Huron Medical Center
People do treat in this scenario for a few reasons...

Radiation Oncologist at Mayo Clinic Hospital
Yeah - I think the challenge with the RCT from Chi...

Radiation Oncologist at Lake Huron Medical Center
All prospective PMRT data that we use as a rationa...

Related Questions